ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / OGI / financials
CATX (33) KZIA (47) SPRB (34) BGM (37) ⌘ Pro Terminal →

Organigram Global Inc. (OGI) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$0.97 +3.43% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.97

Organigram Global Inc. (OGI) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $131.6M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on OGI Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is OGI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Organigram Global Inc. (NASDAQ: OGI) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $0.97 (+3.43% 1D, market cap $131.6M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, OGI ranks #370 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does OGI compare to CATX and KZIA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OGI carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CATX (Perspective Therapeutics Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $131.3M) and KZIA (Kazia Therapeutics Limited) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $132.2M). Among the 5-stock peer group, OGI leads on earnings multiple (N/A) while CATX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for OGI?
▼

For Organigram Global Inc. (OGI), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #370 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.97 (+0.43%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.1% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510045
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- · Rk D
Cash (12)Whales (4)SEC (13)Macro (7)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-6.2% Base Target
$2 Bull$1 Base$1 Bear
📬 FREE OGI RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OGI)Realized 20D OHLCV Swing Band: ±7.5%
Deterministic 5-Pillar Attribution (45/100 Composite)
🔍 WHY OGI SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (27% of score)

SEC XBRL Trailing 12 Months: 0.1% FCF Margin ($3.7M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
37
Grade E$0.92+2.2% Next Q
Q2 (-2Q)
40
Grade D$0.94+0% Next Q
Q3 (-1Q)
42
Grade D$0.94+3.2% Next Q
Current
45
Grade D$0.97-6.3% Hist 90D α
Trajectory: E (37) → D (45)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a OGI Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While OGI currently carries a cautious 45/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.04) and Max Pain ($1.02) forces dealer call-delta covering toward $2.35.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $OGI• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “OGI Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 45%NO 55%Trade / Inspect Odds →
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • Trailing 12 Months

How OGI Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$3.7M (0.1% FCF Margin)
Revenue$4.00BGross Profit $2.08B (52%)Cost of Sales $1.92BOp Profit $1.08B (27%)OpEx (R&D/SG&A) $998.4MNet Profit$865.3M (21.6%)Tax/Other $216.3M
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OGI)

  • ✓Walkthrough of OGI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
OGI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -30.22%▲ ASCENDING CHANNEL
2026-11-03O $0.96H $0.97L $0.93C $0.97VOL 205.1K
RES: $1.44SUP: $0.90SMA50: $1.04SMA200: $1.19
$1.63$1.42$1.21$1.00$0.78RES $1.44SUP $0.90$0.972026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

OGI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 OGI Butterfly Map → + Track OGI →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on OGI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for OGI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for OGI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OGI)

Health Care Rank #370 of 1015 ⚔️ CATX vs OGI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (OGI vs. CATX, KZIA, SPRB, BGM)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Organigram Global Inc. (OGI) ranks #370 by composite RQD confidence (45/100, grade D) and #621 by equity capitalization ($131.6M). Within this direct 5-issuer industry benchmark cohort, OGI leads on earnings valuation at N/A trailing P/E, while CATX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. KZIA currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with OGI at 45/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
OGI ACTIVE
Organigram Global Inc.
D 45/100 — — — +3.43% $131.6M Benchmark Subject
CATX
Perspective Therapeutics Inc.
E 33/100 — — -35.0% -9.56% $131.3M /catx-vs-ogi →
KZIA
Kazia Therapeutics Limited
D 47/100 — — — -5.65% $132.2M /kzia-vs-ogi →
SPRB
Spruce Biosciences Inc.
E 34/100 — — -35.0% -3.97% $133.3M /sprb-vs-ogi →
BGM
BGM Group Ltd. (Class A)
D- 37/100 — 16.6% — 0.00% $127.4M /bgm-vs-ogi →

2. OGI Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Organigram Global Inc. (OGI) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $131.6M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. OGI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is OGI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Organigram Global Inc. (NASDAQ: OGI) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $0.97 (+3.43% 1D, market cap $131.6M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, OGI ranks #370 in composite RQD confidence.

How does OGI compare to CATX and KZIA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OGI carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CATX (Perspective Therapeutics Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $131.3M) and KZIA (Kazia Therapeutics Limited) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $132.2M). Among the 5-stock peer group, OGI leads on earnings multiple (N/A) while CATX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for OGI?

For Organigram Global Inc. (OGI), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #370 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is OGI trading relative to its 50-day, 200-day, and 52-week technical levels?

OGI last traded at $0.97 (+3.43% on volume of 186,372 shares), positioning the stock -6.73% below its 50-day simple moving average ($1.04) and -18.49% below its 200-day simple moving average ($1.19). Across its 52-week range of $0.85 to $2.24, OGI sits at the 8.6% percentile with a 14-day RSI of 41.6 (NEUTRAL RANGE) and an implied next-earnings move of ±7.5% ($1.00 to $1.04).

Direct Sub-Reports: OGI RQD Cockpit OGI 12M Forecast OGI Earnings & Move OGI Dividends & DRIP OGI Insiders & 13F OGI Whale Options OGI Profit Sankey OGI News & Why
ROARABLE RATING BRIEF • RQD 45/100 (D) ✓ SEC XBRL & RQD VERIFIED

OGI — Organigram Global Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

Organigram Global Inc. (OGI) earns a live Roarable RQD composite score of 45/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $0.97 (+3.43% 1D, market capitalization $131.6M).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (4/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Organigram Global Inc. (OGI) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The profile describes a market capitalization of $0.1B. — describes its product lineup, customer base, or revenue model. Per the recent news wire, the company plans to discontinue three cannabis brands as part of a lineup trim and a global cost-saving plan.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 45/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 4/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $0.85 – $2.24 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the source data. The only sector reference available is Health Care / Biotechnology: Pharmaceutical Preparations. An investor should note that the cannabis-brand discontinuation items suggest product-line exposure, but the source provides no supply-chain nodes to trace its ripple effects.

  • Key Question #1: Can OGI sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $2.24 52-week high?
  • Key Question #3: How sensitive is OGI's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

OGI Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Organigram Global Inc. (OGI) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to OGI Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

OGI Bull vs. Bear Conversation Board — What's Your Call at $0.97?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON OGI 🐻 33% BEARISH CONVICTION
1. Pick Your Side on OGI:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $1.08 (+16.1%)
📌 Pinned Debate

Forensic balance sheet and macro-fit pillars score 13 and 15 of 20, with a Piotroski F-Score of 6 of 9 and Debt/Equity of 0.5.

Picked up a starter position in OGI in my $100K Virtual Cash book at $0.93. Forensic balance sheet and macro-fit pillars score 13 and 15 of 20, with a Piotroski F-Score of 6 of 9 and Debt/Equity of 0.5.. Trading inside a $0.85–$2.24 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

EarningsSniper 🐂 BULL

Both sides have a point here — OGI's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $0.73 (-21.5%)
Spot @ $0.93

Zero ROIC and zero FCF yield leave the Fundamental Cash Engine pillar at 12 of 20, with no reported financials to corroborate profitabi

Here is the bear case nobody on the bull side wants to address on OGI: Zero ROIC and zero FCF yield leave the Fundamental Cash Engine pillar at 12 of 20, with no reported financials to corroborate profitability.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE